GlaxoSmithKline UK Ltd

Stockley Park West
Uxbridge
Middlesex
UB11 1BT

Tel. +44 (0)20 8990 9000
Fax. +44 (0)20 8990 4321
www.gsk.com

26th June 2018

Reminder letter regarding the discontinuation of Eperzan▼(albiglutide) 1st July 2018

Subject: Final reminder of Discontinuation of EPERZAN (albiglutide)

Dear Pharmacist,

Following prior communication by GSK in September 2017 and February 2018, this is a final targeted reminder letter to remind you that GSK will discontinue the commercial sale and availability of Eperzan worldwide. **Commercial supplies will no longer be available from GSK in the UK from 1st July 2018.**

You are being sent this reminder because you have dispensed Eperzan from your pharmacy in recent months.

Please note the following:

Suggested Actions

1: For any remaining patients who are still taking Eperzan, discuss with them about making an appointment to see their GP to plan transitioning to an alternative therapy, as soon as possible and prior to the end of June 2018 / available supply.

2: Do not dispense Eperzan for any new patients. Contact the patient's GP and remind them of the discontinuation of Eperzan and seek their advice on what action required eg alternative GLP-1 agonist.

3: Ensure your pharmacy team and the relevant prescriber/s are aware of this information.

Registered in England & Wales
No. 4310159

Registered office
980 Great West Road
Brentford, Middlesex. TW8 9GS

Background and further information

Eperzan▼ (albiglutide) subcutaneous injections (30 mg and 50 mg) have been licenced in the UK since 2014 for adults with type 2 diabetes mellitus. **This withdrawal is on commercial grounds only, and is not related to efficacy or safety of the medicine.** GSK has also communicated this decision to the EMA and the MHRA.

If you have any questions, please contact the Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT; customercontactuk@gsk.com; Freephone: 0800 221441

For medical information enquiries please email ukmedinfo@gsk.com or call 0800 221 441 (option 4)

Yours sincerely,

Dr Mihaela Ianosev
Medical Director
Speciality Care Business Unit, Europe

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

This letter is not a comprehensive description of the risks with the use of EPERZAN. Please refer to the Summary of Product Characteristics available at http://www.medicines.org.uk/emc/